Blocking PYK2 activity may be hypothesized to have an osteogenic impact also in human beings. for at least 10 years has shown good security[13,14]. Raloxifene, bazedoxifene and subcutaneous denosumab, a human being monoclonal antibody that inhibits RANKL, have showed convincing